An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants — FIGARO-BM

Type 2 Diabetes Mellitus Clinical Trial

Official title:
A Non-blinded Retrospective Biomarker add-on Study to FIGARO-DKD for Bioprofiling the Pharmacodynamic Response to Finerenone in FIGARO-DKD Subjects

Status Completed

Clinical Trial Summary

Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), a long-term, progressive decrease in the kidneys' ability to work properly. When CKD happens in people with type 2 diabetes mellitus, a condition characterized by high blood sugar levels, CKD is also referred to as diabetic kidney disease (DKD). FIGARO-BM is an add-on study in which blood draws that were collected in the FIGARO-DKD study are further analyzed. No additional blood draws (also referred to as biological samples) or data will be obtained from the participants, nor will any additional or new study intervention be introduced. No visit or patient contact other than for obtaining the agreement by the patients (also called informed consent) will be required. Inflammation and scarring are both seen as responsible for worsening of chronic kidney disease. There is much information from animal studies that the study treatment finerenone (BAY94-8862) works against inflammation and against scarring (also called fibrosis) in organs such as the kidney. In this exploratory study researchers want to learn more about the study treatment finerenone (BAY94-8862). To find this out, this study will examine substances called biomarkers in blood draws from participants in the FIGARO-DKD study. Biomarkers are used as indicators of biological processes, disease processes or responses to medication. The biomarkers that will be examined stand for inflammation, organ scarring (also called fibrosis), blood vessel function and congestion. The main question of this study is whether there are differences between these biomarkers in the group of participants who received finerenone and the group of participants who received a placebo in the FIGARO-DKD study. A placebo looks like a treatment but does not have any medicine in it. To answer this question, the researchers will compare the levels of these biomarkers between the two groups at different time points after starting the study treatment. Blood samples for this study will be obtained from FIGARO-DKD study sites with a high number of participants who had been treated with finerenone or placebo for at least 24 months. This information will be combined with other information from biomarker examinations already available in the FIGARO-DKD study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05013008
Study type	Interventional
Source	Bayer
Contact
Status	Completed
Phase	Phase 2
Start date	August 18, 2021
Completion date	December 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02771093` - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus	Phase 4
Completed	`NCT02545842` - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)	Phase 4
Recruiting	`NCT03436212` - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.	N/A
Completed	`NCT03244800` - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.	Phase 2
Completed	`NCT03960424` - Diabetes Management Program for Hispanic/Latino	N/A
Withdrawn	`NCT02769091` - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes	Phase 2
Recruiting	`NCT06065540` - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor	Phase 3
Recruiting	`NCT05008276` - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed	`NCT04091373` - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide	Phase 1
Completed	`NCT03296800` - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects	Phase 1
Recruiting	`NCT06212778` - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Completed	`NCT05979519` - Fresh Carts for Mom's to Improve Food Security and Glucose Management	N/A
Recruiting	`NCT05579314` - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)	Phase 1
Completed	`NCT03859934` - Metabolic Effects of Melatonin Treatment	Phase 1
Terminated	`NCT03684642` - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin	Phase 3
Completed	`NCT03248401` - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes	Phase 4
Completed	`NCT03644134` - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns	N/A
Completed	`NCT05295160` - Fasting-Associated Immune-metabolic Remission of Diabetes	N/A
Completed	`NCT02836873` - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment	Phase 3
Completed	`NCT02226003` - Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)	Phase 3